Training and validation dataset (10-fold cross-validation) . | ||
---|---|---|
. | Number of the data . | Percentage of the data . |
Training | 24 336 | 90% |
Validation | 1352 | 10% |
Test-78 | ||
Number of the data | Percentage of the data | |
Positive test set (from literatures) | 39 | 50% |
Negative test set (from DrugBank) | 39 | 50% |
Training and validation dataset (10-fold cross-validation) . | ||
---|---|---|
. | Number of the data . | Percentage of the data . |
Training | 24 336 | 90% |
Validation | 1352 | 10% |
Test-78 | ||
Number of the data | Percentage of the data | |
Positive test set (from literatures) | 39 | 50% |
Negative test set (from DrugBank) | 39 | 50% |
Training and validation dataset (10-fold cross-validation) . | ||
---|---|---|
. | Number of the data . | Percentage of the data . |
Training | 24 336 | 90% |
Validation | 1352 | 10% |
Test-78 | ||
Number of the data | Percentage of the data | |
Positive test set (from literatures) | 39 | 50% |
Negative test set (from DrugBank) | 39 | 50% |
Training and validation dataset (10-fold cross-validation) . | ||
---|---|---|
. | Number of the data . | Percentage of the data . |
Training | 24 336 | 90% |
Validation | 1352 | 10% |
Test-78 | ||
Number of the data | Percentage of the data | |
Positive test set (from literatures) | 39 | 50% |
Negative test set (from DrugBank) | 39 | 50% |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.